Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

Alan H. Bryce*, Neeraj Agarwal, Himisha Beltran, Maha H. Hussain, Oliver Sartor, Neal Shore, Emmanuel S. Antonarakis, Andrew J. Armstrong, Jeremie Calais, Michael A. Carducci, Tanya Barauskas Dorff, Jason A. Efstathiou, Martin Gleave, Leonard G. Gomella, Celestia Higano, Thomas A. Hope, Andrei Iagaru, Alicia K. Morgans, David S. Morris, Michael J. MorrisDaniel P. Petrylak, Robert E. Reiter, Matthew B. Rettig, Charles J. Ryan, Scott B. Sellinger, Daniel E. Spratt, Sandy Srinivas, Scott T. Tagawa, Mary Ellen Taplin, Evan Y. Yu, Tian Zhang, Rana R. McKay, Phillip J. Koo, E. David Crawford

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.

Original languageEnglish (US)
Article numbere35612
Journalcancer
Volume131
Issue number1
DOIs
StatePublished - Jan 1 2025

Funding

Jessica Martin and MJH Life Sciences provided medical writing, editing, and referencing support at the direction of the authors. AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Johnson & Johnson, and Novartis provided financial support for the on\u2010site US Prostate Cancer Conference. The funders had no control, oversight, or other input regarding the faculty invited to attend, the topics covered during the meeting, the questions asked to panel members, or other content discussed during the US Prostate Cancer Conference. The authors developed the article independently without contribution or oversight of the content by any sponsors, who had no role in the article content, development, or approval process. Emmanuel S. Antonarakis was supported in part by the National Cancer Institute (Grant P30 CA077598) and the US Department of Defense (Grant W81XWH\u201022\u20102\u20100025).

Keywords

  • advanced prostate cancer
  • androgen receptor pathway inhibitors
  • biochemical recurrence
  • consensus recommendations
  • poly(ADP-ribose) polymerase (PARP) inhibitors
  • radioligand therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024'. Together they form a unique fingerprint.

Cite this